Improving Public Cancer Care by Implementing Precision Medicine in Norway

IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.

NCT Number	NCT04817956
Lead Sponsor	Oslo University Hospital Collaborators: Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Conditions	Cancer Metastatic
Enrollment	3,000 participants
Start Date	2021-04-01
Primary Completion	2040-03-30 (estimated)
Study Completion	2045-04-30 (estimated)
Updated on ClinicalTrials.gov	2024-02-29